Abstract
Multikinase inhibitors (MKIs, eg, sorafenib and sunitinib) are oral anticancer agents associated with handfoot skin reaction (HFSR), a cutaneous adverse event affecting 20%-40% of patients treated with these drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently provided the first consensus recommendations for the management of MKI-associated HFSR.
Original language | English |
---|---|
Pages (from-to) | 23-29 |
Number of pages | 7 |
Journal | Community Oncology |
Volume | 7 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jan 2010 |